厄洛替尼联合全脑放疗治疗非小细胞肺癌脑转移的临床观察  

A Clinical Observation of Concomitant Therapy of Erlotinib and Whole Brain Radiotherapy in Patients of NSCLC Combined with Brain Metastases

作　　者：赵荆[1] 付强[1] 张莉红[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院肿瘤科,武汉430030

出　　处：《中国肺癌杂志》2009年第12期1291-1294,共4页Chinese Journal of Lung Cancer

摘　　要：背景与目的非小细胞肺癌脑转移灶的治疗包括手术及放化疗,但脑转移灶的控制率均不佳,患者中位生存期4-6个月。小分子酪氨酸激酶抑制剂厄洛替尼容易进入血脑屏障,单药使用时可控制脑转移灶的生长。本次临床观察的目的是评价厄洛替尼联合全脑放疗对非小细胞肺癌脑转移患者的疗效及毒副反应。方法回顾性研究肿瘤科2006年-2009年间12例非小细胞肺癌脑转移患者。均采用厄洛替尼口服联合全脑放疗,其中厄洛替尼剂量为150mg/d;全脑放疗的剂量为(3000-3600)cGy/(10-12)F。放疗完成后2月内评价近期疗效。结果脑转移灶控制率为91.7%,其中PR66.7%,SD25%。副反应主要是皮疹(75%)和乏力(91.7%)。结论厄洛替尼联合全脑放疗对非小细胞肺癌脑转移灶的疗效高于单纯全脑放疗,且毒副反应可以耐受。Background and objective Treatments to brain metastases in patients of NSCLC include operation,chemotherapy and radiotherapy,while the disease control rate of brain lesions is not so good,the media survival time is 4-6 months.Tyrosine kinase inhibitor erlotinib can get into blood-brain barrier as reported,and it is used as a effetive method to control brain metastases.The aim of this clinical observation was to evaluate the efficacy and adverse reactions after concomitant therapy of erlotinib and whole brain radiotherapy （WBRT） in patients of NSCLC with brain metastasis.Methods This was a retrospective study.From 2006 to 2009,There were 12 cases of NSCLC with brain metastases.They were accepted the concomitant therapy of erlotinib and WBRT.The dose of erlotinib was 150 mg/d and the radiotherapy dose was （3 000-3 600） cGy/（10-12） F.After 2 months of radiotherapy the early efficacy was evaluabed.Results The control rate of brain metastases was 91.7% with PR 66.7%,SD 25%.The major adverse reactions were skin rash （75%） and fatigue （91.7%）.Conclusion The effect of the concomitant of erlotinib and WBRT in patients of NSCLC with brain metastases is better than WBRT alone,and the concomitant therapy is well tolerated.

关 键 词：厄洛替尼 全脑放疗 肺肿瘤 临床观察 

分 类 号：R734.2[医药卫生—肿瘤]